Indivior (INDV) announced results from a randomized, double-blind clinical trial published in JAMA Network Open. The study found that both the ...

A new study led by researchers at Wake Forest University School of Medicine and Atrium Health Levine Cancer has found that a ...

Average-risk women were guided to get mammograms every two years, while low-risk individuals were advised to have no screening until they became higher risk or reached age 50.

Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient has been randomized in the RASolute ...

Neurocrine Biosciences ($NBIX) announced an update on their ongoing clinical study. Neurocrine Biosciences has announced the initiation of a Phase ...

Vixarelimab showed significant symptom relief and disease progression reduction in prurigo nodularis compared with placebo across all doses. A phase 2b trial found vixarelimab rapidly reduced itch and ...

Immunome (IMNM) surges after positive phase 3 results for varegacestat in desmoid tumors. Read the latest analysis on the ...

This study protocol outlines a 12-week randomized trial testing whether a MIND diet intervention is feasible, acceptable, and ...